Bioresorbable Scaffolds Market Introduction 

Bioresorbable scaffolds are medical devices that are used to provide temporary support to a damaged or blocked blood vessel. These scaffolds are made of materials that can be absorbed and metabolized by the body over time, eliminating the need for permanent implantation.The bioresorbable scaffolds market has been growing rapidly in recent years due to an increase in the prevalence of cardiovascular diseases and the growing demand for minimally invasive procedures. These devices offer several advantages over traditional stents, including the elimination of the risk of restenosis (re-narrowing of the blood vessel), reduced risk of thrombosis (blood clotting), and improved long-term outcomes.The market for bioresorbable scaffolds is segmented by material type, application, end-user, and geography. The most commonly used materials in bioresorbable scaffolds include polymers, metals, and ceramics. Applications of bioresorbable scaffolds include coronary artery disease, peripheral artery disease, and others. End-users of these devices include hospitals, clinics, and ambulatory surgical centers.Geographically, the market for bioresorbable scaffolds is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe currently dominate the market due to the high prevalence of cardiovascular diseases in these regions and the availability of advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness significant growth in the coming years due to the increasing adoption of minimally invasive procedures and the rising healthcare expenditure in developing countries.Overall, the bioresorbable scaffolds market is expected to continue growing in the coming years due to the growing demand for minimally invasive procedures and the increasing prevalence of cardiovascular diseases.

Bioresorbable Scaffolds Market  Size

The global bioresorbable scaffolds market size was valued at $346 million in 2020 and is projected to reach $1.30 billion by 2028, growing at a CAGR of 17.5% from 2021 to 2028.The market growth is driven by several factors, including the increasing prevalence of cardiovascular diseases, the growing demand for minimally invasive procedures, and the advantages of bioresorbable scaffolds over traditional stents. Additionally, the development of innovative bioresorbable materials and the increasing adoption of bioresorbable scaffolds in emerging markets are expected to further drive market growth in the coming years.Geographically, North America and Europe currently dominate the bioresorbable scaffolds market due to the high prevalence of cardiovascular diseases in these regions and the availability of advanced healthcare infrastructure. However, the Asia Pacific region is expected to witness significant growth in the coming years due to the increasing adoption of minimally invasive procedures and the rising healthcare expenditure in developing countries.

Bioresorbable Scaffolds Market  Share

The bioresorbable scaffolds market is highly fragmented, with several players operating in the market. Some of the key players in the market include Abbott Laboratories, Biotronik SE & Co. KG, Boston Scientific Corporation, Kyoto Medical Planning Co. Ltd., Amaranth Medical Inc., Elixir Medical Corporation, Arterial Remodeling Technologies SA, Reva Medical Inc., and Meril Life Sciences Pvt. Ltd.Abbott Laboratories held the largest share of the global bioresorbable scaffolds market in 2020, followed by Biotronik SE & Co. KG and Boston Scientific Corporation. Abbott Laboratories has a strong product portfolio in the bioresorbable scaffolds market, including its Absorb bioresorbable vascular scaffold, which received approval from the U.S. Food and Drug Administration (FDA) in 2016.However, the market share of these companies can vary based on different regions and segments of the market. The bioresorbable scaffolds market is highly competitive, with companies focusing on product innovation, partnerships, and strategic collaborations to maintain their market position and increase their market share

Bioresorbable Scaffolds Market  Trends

Here are some key trends in the bioresorbable scaffolds market:

1. Increasing use of bioresorbable scaffolds in coronary artery disease: Bioresorbable scaffolds are increasingly being used in the treatment of coronary artery disease, which is a major cause of mortality and morbidity worldwide. The use of these scaffolds in coronary artery disease offers several advantages over traditional stents, including reduced risk of restenosis and improved long-term outcomes.
2. Development of innovative bioresorbable materials: Companies are investing in the development of new and innovative bioresorbable materials for use in scaffolds. For example, researchers are exploring the use of magnesium-based alloys and silk-based materials for bioresorbable scaffolds.
3. Growing demand for minimally invasive procedures: There is a growing demand for minimally invasive procedures in the treatment of cardiovascular diseases. Bioresorbable scaffolds offer a minimally invasive alternative to traditional stents, which require permanent implantation.
4. Increasing adoption of bioresorbable scaffolds in emerging markets: The adoption of bioresorbable scaffolds is increasing in emerging markets, particularly in Asia Pacific and Latin America. This is driven by factors such as increasing healthcare expenditure, growing awareness about minimally invasive procedures, and the rising prevalence of cardiovascular diseases.
5. Rising focus on clinical trials: There is a growing focus on conducting clinical trials to evaluate the safety and efficacy of bioresorbable scaffolds. This is important for gaining regulatory approval and for increasing the adoption of these devices in clinical practice.

Bioresorbable Scaffolds Market Driving factors

Here are some key driving factors for the bioresorbable scaffolds market:

1. Increasing prevalence of cardiovascular diseases: The rising incidence of cardiovascular diseases, such as coronary artery disease and peripheral artery disease, is driving the demand for bioresorbable scaffolds. These scaffolds provide a minimally invasive alternative to traditional stents and offer several advantages, including reduced risk of restenosis and improved long-term outcomes.
2. Advantages over traditional stents: Bioresorbable scaffolds offer several advantages over traditional stents, including the elimination of the risk of restenosis, reduced risk of thrombosis, and improved long-term outcomes. This has led to increased adoption of bioresorbable scaffolds in the treatment of cardiovascular diseases.
3. Growing demand for minimally invasive procedures: There is a growing demand for minimally invasive procedures in the treatment of cardiovascular diseases. Bioresorbable scaffolds offer a minimally invasive alternative to traditional stents, which require permanent implantation.
4. Technological advancements in bioresorbable materials: Technological advancements in bioresorbable materials, such as polymers and metals, have led to the development of more advanced and effective bioresorbable scaffolds. This has further driven the adoption of bioresorbable scaffolds in clinical practice.
5. Increasing healthcare expenditure: The increasing healthcare expenditure in developing countries is driving the adoption of advanced medical devices, such as bioresorbable scaffolds. This is particularly true in Asia Pacific and Latin America, where the adoption of bioresorbable scaffolds is increasing rapidly.

Bioresorbable Scaffolds Market  Reginal Analysis

Here's a brief regional analysis of the bioresorbable scaffolds market:

1. North America: North America dominates the bioresorbable scaffolds market due to the high prevalence of cardiovascular diseases and the availability of advanced healthcare infrastructure. The U.S. is the largest market in the region, accounting for a significant share of the global market.
2. Europe: Europe is the second-largest market for bioresorbable scaffolds, driven by factors such as the growing adoption of minimally invasive procedures, the increasing prevalence of cardiovascular diseases, and the favorable reimbursement policies for medical devices.
3. Asia Pacific: The Asia Pacific region is expected to witness significant growth in the coming years due to the increasing adoption of minimally invasive procedures, the rising healthcare expenditure in developing countries, and the growing prevalence of cardiovascular diseases. China, India, and Japan are the largest markets in the region.
4. Latin America: The bioresorbable scaffolds market in Latin America is growing due to the increasing adoption of advanced medical devices, the growing prevalence of cardiovascular diseases, and the rising healthcare expenditure in the region.
5. Middle East & Africa: The Middle East & Africa region is expected to witness moderate growth in the coming years due to the increasing adoption of minimally invasive procedures and the growing prevalence of cardiovascular diseases in the region. The UAE, Saudi Arabia, and South Africa are the largest markets in the region

Bioresorbable Scaffolds Market  Forecasts 2030

The bioresorbable scaffolds market is expected to grow significantly in the coming years. Here are some forecasts for the market by 2030:

1. Market size: The global bioresorbable scaffolds market is expected to reach USD 1.6 billion by 2030, growing at a CAGR of 8.3% from 2021 to 2030.
2. Region-wise growth: Asia Pacific is expected to witness the highest growth during the forecast period, driven by the increasing adoption of minimally invasive procedures and the rising prevalence of cardiovascular diseases in the region.
3. Product-wise growth: Polymeric bioresorbable scaffolds are expected to witness the highest growth during the forecast period, owing to their favorable mechanical properties, biocompatibility, and ease of handling.
4. Application-wise growth: The coronary artery disease segment is expected to dominate the market during the forecast period, driven by the increasing prevalence of the disease worldwide and the growing adoption of bioresorbable scaffolds as a minimally invasive alternative to traditional stents.
5. Key players: The key players in the bioresorbable scaffolds market include Abbott Laboratories, BIOTRONIK SE & Co. KG, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., and REVA Medical Inc.

Overall, the bioresorbable scaffolds market is expected to witness significant growth in the coming years, driven by the increasing adoption of minimally invasive procedures, the rising prevalence of cardiovascular diseases, and the technological advancements in bioresorbable materials.

Bioresorbable Scaffolds Market Key Industry Players

Here are some of the key players in the bioresorbable scaffolds market:

1. Abbott Laboratories: Abbott Laboratories is a leading player in the bioresorbable scaffolds market, with a strong portfolio of products, including the Absorb Bioresorbable Vascular Scaffold System.
2. BIOTRONIK SE & Co. KG: BIOTRONIK SE & Co. KG is a German company that offers a range of bioresorbable scaffolds, including the Magmaris Magnesium Bioresorbable Scaffold.
3. Elixir Medical Corporation: Elixir Medical Corporation is a U.S.-based company that offers the DESolve Bioresorbable Scaffold, which is designed to treat coronary artery disease.
4. Kyoto Medical Planning Co. Ltd.: Kyoto Medical Planning Co. Ltd. is a Japanese company that offers the MeRes100 Bioresorbable Scaffold, which is designed for the treatment of coronary artery disease.
5. REVA Medical Inc.: REVA Medical Inc. is a U.S.-based company that offers the Fantom Bioresorbable Scaffold, which is made from Tyrocore, a proprietary polymer that is designed to provide optimal strength and support.

Other notable players in the market include Amaranth Medical, Arterius Limited, Meril Life Sciences Pvt. Ltd., and Terumo Corporation. These companies are investing in R&D activities to develop more advanced and effective bioresorbable scaffolds to meet the growing demand for minimally invasive procedures in the treatment of cardiovascular diseases.